FDA approves private label ibuprofen PM
This article was originally published in The Tan Sheet
FDA approves Perrigo's OTC ibuprofen and diphenhydramine citrate tablets, the Allegan, Mich.-based private-labeler says Dec. 29. Perrigo will ship the product in the first quarter of 2009. Estimated sales of the comparable Wyeth Consumer Healthcare product, Advil PM tablets, were $70 million in the 12 months ending Sept. 28 (1"The Tan Sheet" Nov. 3, 2008, In Brief)
You may also be interested in...
The company says Oct. 29 it expects final clearance to launch a private-label version of Wyeth Consumer Healthcare's Advil PM tablets after Wyeth's exclusivity ends, Dec. 21, 2008. FDA granted tentative approval for Perrigo's abbreviated new drug application for the non-steroidal anti-inflammatory drug (ibuprofen 200 mg and diphenhydramine citrate 38 mg) indicated as a pain reliever and sleep-aid. According to Allegan, Mich.-based Perrigo, Advil PM U.S. sales totaled $70 million in the 12 months ending Sept. 28. Perrigo includes sales of an ibuprofen/diphenhydramine citrate product in the $275 million it expects to generate from more than 25 products launched between February 2007 and June 2009 (1"The Tan Sheet" Aug. 25, 2008, p. 11)
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.